Cencora stock holds firm as revenue and profit trends stay in focus

Cencora Inc. (US15135B1017) stock is trading around its latest reported business profile, with the company posting $294.0 billion in fiscal 2025 revenue, $2.6 billion in net income and $3.9 billion in operating cash flow. Those figures frame the current investment case more clearly than any short-term headline, because distribution scale and cash generation remain the core drivers.

Revenue at $294.0 billion

In fiscal 2025, Cencora reported revenue of $294.0 billion, compared with $262.2 billion in fiscal 2024. That is an increase of $31.8 billion, or 12.1%, and it shows how much volume moved through the companys distribution network over the year.

Net income rose to $2.6 billion in fiscal 2025 from $2.2 billion a year earlier, while operating cash flow reached $3.9 billion versus $3.4 billion in fiscal 2024. The comparison matters because it shows that higher sales were accompanied by stronger earnings and cash generation, not just top-line growth.

Cash flow widened

Operating cash flow increased by $0.5 billion year over year to $3.9 billion in fiscal 2025, a 14.7% rise from the prior year. For a distributor, that kind of cash conversion is often more useful than a single-day share move, because it underpins inventory, working capital and capital-return decisions.

The business also remained tied to a large and stable demand base in pharmaceuticals, with its scale reflected in the $294.0 billion revenue base for fiscal 2025. That makes Cencora one of the most important names in drug distribution rather than a simple margin story.

Distribution scale matters

Cencora's core role is pharmaceutical distribution and related services, which means its revenue is driven by transaction volume, customer reach and reimbursement dynamics rather than consumer branding. In fiscal 2025, that model produced $294.0 billion in revenue, $2.6 billion in net income and $3.9 billion in operating cash flow.

For readers tracking the stock, the key comparison is the 12.1% revenue increase and the 14.7% rise in operating cash flow in fiscal 2025. Those two gains suggest the company kept its scale advantage while improving the quality of its earnings base.

Closing level and valuation

Cencora stock is best judged against the latest annual report metrics until a new market catalyst changes the picture, because the fiscal 2025 numbers remain the clearest published reference point. The company ended fiscal 2025 with $294.0 billion in revenue, $2.6 billion in net income and $3.9 billion in operating cash flow, all dated to fiscal 2025.

As a valuation read-through, investors are left to balance that scale against the pace of earnings growth and cash generation. The numbers available point to a large, cash-generative distributor whose latest reported year was still growing in absolute terms.

Pharmaceutical distribution

Cencora's pharmaceutical distribution business is the main engine behind the reported fiscal 2025 figures. Revenue of $294.0 billion in that year shows how the segment sits at the center of US drug supply chains, while the $3.9 billion in operating cash flow highlights the working-capital intensity of the model.

Stock profile

Cencora stock remains a large-cap US healthcare distribution name, and its latest fiscal year gives the clearest benchmark for the market. The company traded on the NYSE under the ticker COR, with fiscal 2025 still the latest full-year reference for revenue, profit and cash flow.